Bacterial infections are major life-threatening complications in patients receiving cytotoxic drugs. These
infections generally occur during periods of
neutropenia. It has been suggested that the incidence of
neutropenia correlates with the incidence of
infections. A synthetic hexapeptide,
WKYMVm, which stimulates
phosphoinositide hydrolysis in leukocytes, has been shown to activate microbicidal activities of human polymorphonuclear neutrophils. In this study, we evaluate whether
WKYMVm stimulates bactericidal activity in neutrophils obtained from patients who received
chemotherapy for solid
tumors when they were neutropenic. Eight patients and 11 healthy controls were recruited for the study. Patient neutrophils, on day 0 and at 2 weeks after
chemotherapy, were collected. Expression of the
WKYMVm peptide receptor, on leukocytes, was analyzed by
fluorescein-activated cell sorting. Neutrophil bactericidal assays were performed using both
reactive oxygen species generation and intracellular killing. Expression of the
WKYMVm peptide receptor on leukocytes showed no difference in the treated patients compared to healthy controls.
WKYMVm increased bactericidal activities, in a dose-dependent fashion, of control neutrophils compared to treated patient neutrophils obtained on day 0.
WKYMVm markedly stimulated bactericidal activity of treated patient neutrophils obtained at 2 weeks after
chemotherapy compared to treated patient neutrophils obtained on day 0.
WKYMVm augmented neutrophil bactericidal activity was noted at low concentration but was suppressed at higher concentrations of
5-fluorouracil.
WKYMVm augmented neutrophil bactericidal activity was not suppressed by
cisplatin.
WKYMVm has the potential for increasing neutrophil bactericidal activity in
chemotherapy-treated
cancer patients.